Trials / Completed

CompletedNCT00376064

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 20 (actual)

Sponsor: Novartis Pharmaceuticals · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy

Conditions

Acromegaly

Interventions

Type	Name	Description
DRUG	Octreotide acetate and cabergoline/Octrotide and Somavert

Timeline

Start date: 2006-03-01
Primary completion: 2010-01-01
First posted: 2006-09-14
Last updated: 2017-03-06

Locations

16 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT00376064. Inclusion in this directory is not an endorsement.